Related references
Note: Only part of the references are listed.Diagnosis and Management of Multiple Myeloma A Review
Andrew J. Cowan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
Franziska Fuechsl et al.
CELLS (2022)
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma
Haiming Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Protein tyrosine phosphatases in multiple myeloma
Pegah Abdollahi et al.
CANCER LETTERS (2021)
Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
Sinan Xiong et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Ignacio J. Cardona-Benavides et al.
CELLS (2021)
A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics
Hassan Awada et al.
CELLS (2021)
Daratumumab for the treatment of multiple myeloma
S. R. Goldsmith et al.
DRUGS OF TODAY (2021)
Bispecific Antibodies in Multiple Myeloma: Present and Future
Guido Lancman et al.
BLOOD CANCER DISCOVERY (2021)
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression
Haiming Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
Phaik Ju Teoh et al.
HAEMATOLOGICA (2020)
Anti-myeloma potential of ruxolitinib in co-existing JAK2V617F-positive smouldering myeloma and polycythaemia vera
Holly Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
James R. Berenson et al.
CLINICAL CANCER RESEARCH (2020)
Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multible myeloma via ERK/STAT3 axis
Zhaoyuan Zhang et al.
AGING-US (2020)
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
A. Romano et al.
SCIENTIFIC REPORTS (2020)
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
Daisuke Ogiya et al.
BLOOD (2020)
Signal transduction via integrin adhesion complexes
Jonathan D. Humphries et al.
CURRENT OPINION IN CELL BIOLOGY (2019)
Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors
Nikhil R. Tasker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma
Phyllis S. Y. Chong et al.
CANCER RESEARCH (2019)
B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3
Liang Lin et al.
LEUKEMIA (2019)
Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis
Phaik Ju Teoh et al.
BLOOD (2018)
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
Eva De Smedt et al.
FRONTIERS IN ONCOLOGY (2018)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients
Mariana B. de Oliveira et al.
CANCER LETTERS (2017)
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
Vikas A. Gupta et al.
BLOOD (2017)
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
M. B. Meads et al.
ONCOGENE (2016)
Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
Jinheng Wang et al.
JOURNAL OF PATHOLOGY (2016)
The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells
Tobias S. Slordahl et al.
ONCOTARGET (2016)
The emerging roles of exosomes in leukemogeneis
Jianbiao Zhou et al.
ONCOTARGET (2016)
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
Michinori Ogura et al.
CANCER SCIENCE (2015)
Genomic heterogeneity in multiple myeloma
Raphael Szalat et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2015)
Formation and role of exosomes in cancer
Lindsey T. Brinton et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia
Phyllis S. Y. Chong et al.
CANCER RESEARCH (2014)
Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia
Jianbiao Zhou et al.
EXPERIMENTAL HEMATOLOGY (2014)
Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro
Sung-Hoon Jung et al.
EXPERIMENTAL HEMATOLOGY (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Management of multiple myeloma in Asia: resource-stratified guidelines
Daryl Tan et al.
LANCET ONCOLOGY (2013)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo et al.
CLINICAL CANCER RESEARCH (2011)
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival
A. Scuto et al.
LEUKEMIA (2011)
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
K. A. Monaghan et al.
LEUKEMIA (2011)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2010)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase
Haihe Wang et al.
CANCER CELL (2010)
INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
Jun Li et al.
NEOPLASIA (2010)
β1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Kenneth H. Shain et al.
CANCER RESEARCH (2009)
Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains
Jonathan M. Wojciak et al.
EMBO JOURNAL (2009)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Renate Burger et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
Unn-Merete Fagerli et al.
BLOOD (2008)
A role for IFN-λ1 in multiple myeloma B cell growth
A. J. Novak et al.
LEUKEMIA (2008)
IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3
N Tsuyama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation
M Snyder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma
P Tassone et al.
CLINICAL CANCER RESEARCH (2005)
Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
AC Bharti et al.
BLOOD (2004)
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells
M Chatterjee et al.
BLOOD (2004)
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Y Nefedova et al.
JOURNAL OF IMMUNOLOGY (2004)
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
K Brocke-Heidrich et al.
BLOOD (2004)
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway
M Chatterjee et al.
BLOOD (2002)
A phosphatase associated with metastasis of colorectal cancer
S Saha et al.
SCIENCE (2001)
The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells
D Hönemann et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone
P Tassone et al.
CELL DEATH AND DIFFERENTIATION (2000)
Share Paper
